Financial Performance
5Y price score: 246
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 473.6%
US$ Per
Share
By default your notes are visible only to you.
374.1
52-week range
555.6
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2.7 %
Dividend Yield TTM
-
Market cap $
$ 140,316
Price / Earnings TTM
32.2
Price / Book TTM
6.9
PEG TTM
4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
42.1 %
174.6 %
473.6 %
Free cash flow per share growth
10.6 %
8.9 %
827.3 %
Earnings per share growth
8 %
48.9 %
763.2 %
Founded: 1,989
Employees: 6,100
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Aug 3, 2026)
1) Strong Financial Performance and Growth Drivers
- Vertex reported Q2 2026 total revenue of $3.3 billion, a 12% YoY increase.
- Global CF revenue grew 11% YoY, with significant contributions from ALYFTREK and newer products CASGEVY ($76 million) and JOURNAVX ($50 million).
- The company raised its full-year revenue guidance to $13.1 billion to $13.2 billion, reflecting strong performance across its CF franchise and non-CF products.
2) Pipeline Advancements and Regulatory Progress
- Vertex is advancing its R&D pipeline, with key milestones including the acceptance of the BLA for Pove in IgAN, set for a November 30 PDUFA date.
- Enrollment in pivotal studies is progressing, with VX-407 in ADPKD and AMPLITUDE in AMKD on track for completion by year-end.
- The company is also preparing for the initiation of VX-017 Phase I/II study in type 1 diabetes, targeting a broader patient population.
3) Strategic Acquisition of Crinetics Pharmaceuticals
- Vertex announced a definitive agreement to acquire Crinetics Pharmaceuticals, adding a fifth pillar in rare endocrine diseases to its portfolio.
- The acquisition is expected to enhance Vertex's R&D pipeline and accelerate revenue growth, with peak sales potential of $5 billion from Crinetics' lead assets.
- The transaction is anticipated to close in Q3 2026, positioning Vertex for sustained growth.
4) Commercial Momentum in CF and Pain Franchises
- ALYFTREK surpassed $1 billion in revenue in H1 2026, with strong uptake in both the U.S. and Europe.
- CASGEVY's revenue growth reflects its recent FDA approval for pediatric use, while JOURNAVX is gaining traction with 70% sequential growth in revenue.
- The company is focused on expanding access and prescription growth for JOURNAVX, with ongoing efforts to secure broader payer coverage.
5) Challenges and Competitive Landscape
- Vertex faces competition in the IgAN space, particularly regarding eGFR outcomes from competitors, which may impact Pove's market entry.
- The company is also navigating the complexities of formulary access and reimbursement dynamics for JOURNAVX, which may affect revenue growth.
- Further details on competitive positioning and clinical data from ongoing trials are expected in upcoming months, particularly for AMPLITUDE and DM1 programs.
Bottom line: Vertex Pharmaceuticals is well-positioned for continued growth, driven by strong financial performance, a robust pipeline, and strategic acquisitions, despite facing competitive pressures and operational challenges in certain therapeutic areas.
Annual Reports, Presentations And IR Contacts
Go to the websiteVertex Pharmaceuticals Incorporated — Financial Overview, Stock Price, Market Cap
Vertex Pharmaceuticals Incorporated is a company. Founded in 1989. As of August 26, 2026, the company's market capitalization is $140316094250 with a current stock price of $552.85.